Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
PRTA - Prothena Corporation plc
Market Cap 3.56B P/E - EPS this Y 16.30% Ern Qtrly Grth -
Income -50.92M Forward P/E -16.55 EPS next Y -85.30% 50D Avg Chg -1.00%
Sales 217.25M PEG -0.21 EPS past 5Y - 200D Avg Chg 13.00%
Dividend N/A Price/Book 5.86 EPS next 5Y 34.07% 52W High Chg -15.00%
Recommedations 1.90 Quick Ratio 12.07 Shares Outstanding 53.78M 52W Low Chg 170.00%
Insider Own 12.42% ROA -8.36% Shares Float 38.35M Beta 0.18
Inst Own 96.22% ROE -8.75% Shares Shorted/Prior 5.72M/5.38M Price 67.53
Gross Margin -11.13% Profit Margin -23.44% Avg. Volume 420,893 Target Price 61.21
Oper. Margin 44.22% Earnings Date Nov 4 Volume 273,605 Change -2.20%
Healthcare | Biotechnology | Ireland
About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc News
12/19/24 Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
12/19/24 Prothena’s Parkinson’s study fails primary endpoint despite some success
12/19/24 Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
12/12/24 Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
11/15/24 Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
11/13/24 Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
11/12/24 Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
11/12/24 Prothena: Q3 Earnings Snapshot
11/12/24 Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
11/11/24 Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
11/05/24 Prothena to Report Third Quarter 2024 Financial Results on November 12
10/29/24 Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
10/29/24 Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
09/25/24 Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
08/29/24 Prothena to Participate in Upcoming Healthcare Conferences
08/19/24 What Makes Prothena (PRTA) a New Buy Stock
08/17/24 Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks
08/09/24 Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
08/08/24 Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
08/08/24 Prothena: Q2 Earnings Snapshot
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Jan 24 Sell 34 5,000 170,000 01/24/24
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Jan 24 Option 13.53 5,000 67,650 5,000 01/24/24
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Dec 20 Sell 37.06 5,000 185,300 12/20/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Dec 20 Option 13.53 5,000 67,650 5,000 12/20/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Nov 30 Sell 34 5,000 170,000 11/30/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Nov 30 Option 13.53 5,000 67,650 5,000 11/30/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Oct 25 Sell 41.31 5,000 206,550 10/25/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Oct 25 Option 13.53 5,000 67,650 5,000 10/25/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Oct 11 Option 11.12 4,000 44,480 4,000 10/11/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Oct 11 Sell 47.18 4,000 188,720 10/11/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Oct 04 Sell 46.9 5,000 234,500 10/04/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Oct 04 Option 12.15 5,000 60,750 5,000 10/04/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Sep 27 Sell 47.8 5,000 239,000 09/27/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Sep 27 Option 10.27 5,000 51,350 5,000 09/27/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Sep 19 Sell 52.36 5,000 261,800 09/19/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Sep 19 Option 15.04 5,000 75,200 5,000 09/19/23
Garren Hideki Chief Medical Office.. Chief Medical Officer Sep 13 Sell 55.48 2,000 110,960 09/13/23
Garren Hideki Chief Medical Office.. Chief Medical Officer Sep 13 Option 24.9 2,000 49,800 2,000 09/13/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Sep 13 Sell 55.72 4,000 222,880 09/13/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Sep 13 Option 11.12 4,000 44,480 4,000 09/13/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Sep 06 Sell 55.02 5,000 275,100 09/06/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Sep 06 Option 12.15 5,000 60,750 5,000 09/06/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Aug 30 Sell 55.39 5,000 276,950 08/30/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Aug 30 Option 10.27 5,000 51,350 5,000 08/30/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Aug 18 Option 15.04 5,000 75,200 5,000 08/18/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Aug 18 Sell 57.18 5,000 285,900 08/18/23
Garren Hideki Chief Medical Office.. Chief Medical Officer Aug 16 Sell 58.94 2,000 117,880 08/16/23
Garren Hideki Chief Medical Office.. Chief Medical Officer Aug 16 Option 24.9 2,000 49,800 2,000 08/16/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Aug 16 Sell 59.1 4,000 236,400 08/16/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Aug 16 Option 11.12 4,000 44,480 4,000 08/16/23
Zago Wagner M. Chief Scientific Off.. Chief Scientific Officer Aug 02 Sell 67.53 4,000 270,120 08/02/23
Zago Wagner M. Chief Scientific Off.. Chief Scientific Officer Aug 02 Option 12.15 4,000 48,600 4,000 08/02/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Aug 02 Sell 67.45 5,000 337,250 08/02/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Aug 02 Option 12.15 5,000 60,750 5,000 08/02/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Jul 26 Sell 62.62 5,000 313,100 07/26/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Jul 26 Option 10.27 5,000 51,350 5,000 07/26/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Jul 19 Option 15.04 5,000 75,200 5,000 07/19/23
Walker Karin L Chief Accounting Off.. Chief Accounting Officer Jul 19 Sell 69.52 5,000 347,600 07/19/23
Garren Hideki Chief Medical Office.. Chief Medical Officer Jul 12 Sell 67.84 2,000 135,680 07/12/23
Garren Hideki Chief Medical Office.. Chief Medical Officer Jul 12 Option 24.9 2,000 49,800 2,000 07/12/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Jul 12 Sell 67.67 4,000 270,680 07/12/23
Smith Brandon S. Chief Operating Offi.. Chief Operating Officer Jul 12 Option 11.12 4,000 44,480 4,000 07/12/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Jul 05 Sell 68.34 5,000 341,700 07/05/23
Karp Carol D. Chief Regulatory Off.. Chief Regulatory Officer Jul 05 Option 12.15 5,000 60,750 5,000 07/05/23
Zago Wagner M. Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 68.34 4,000 273,360 07/05/23
Zago Wagner M. Chief Scientific Off.. Chief Scientific Officer Jul 05 Option 12.15 4,000 48,600 4,000 07/05/23
Selkoe Dennis J. Director Director Jul 03 Sell 67.43 5,000 337,150 2,845 07/03/23
Selkoe Dennis J. Director Director Jul 03 Option 11.33 5,000 56,650 7,845 07/03/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Jun 28 Sell 69.93 5,000 349,650 06/28/23
Malecek Michael J Chief Legal Officer Chief Legal Officer Jun 28 Option 10.27 5,000 51,350 5,000 06/28/23